ENTX

Insider Trades

Name	Value	Action	Price	Current Price
Germano Geno JDirector $26k20k shares BuyMar 9, 2026 $1.30 --
Ellis SeanDirector $12k10k shares BuyMar 5, 2026 $1.23 --
Germano Geno JDirector $30k20k shares BuyFeb 10, 2026 $1.49 --
Taitel HayaDirector $11k7.5k shares BuyFeb 10, 2026 $1.48 --
Ellis SeanDirector $22k18k shares BuyFeb 9, 2026 $1.24 --
Toledano Miranda JayneDirector, Officer: Chief Executive Officer $20k11k shares BuyDec 29, 2025 $1.81 --

Trade ENTX

About Entera Bio Ltd.

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

CEO: Miranda J. Toledano
IPO Date: Jun 28, 2018

Market Data

Open: $1.20
High: $1.22
Low: $1.17
Volume: 50.8K
Avg Volume: 153.3K
52W High: $3.22
52W Low: $0.91

Valuation

Market Cap: $60M
Enterprise Value: $56M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-7.5M
Revenue: $42k
Net Income: $-11M
Cash: $7.1M
Debt: $490k

Events

EarningsAug 14

EPS est. -0.08